EFTR fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
EFTR does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company